Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alternative hypothesis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    83 result(s) found for: Alternative hypothesis. Displaying page 4 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2012-003633-42 Sponsor Protocol Number: RBHIPF004 Start Date*: 2013-10-18
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust
    Full Title: A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
    Medical condition: A diagnosis of connective tissue disease associated interstitial lung disease, based on internationally accepted criteria, in one of the following categories: o Systemic sclerosis o Idiopathic inte...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10022611 Interstitial lung disease PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10027754 Mixed connective tissue disease PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039710 Scleroderma PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10036102 Polymyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-001049-24 Sponsor Protocol Number: ACW0002 Start Date*: 2017-04-03
    Sponsor Name:Actinogen Medical
    Full Title: XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects with Mild Dementia due to Alzheimer’s Disea...
    Medical condition: Mild Dementia due to Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002100-13 Sponsor Protocol Number: ESR-16-12611 Start Date*: 2018-10-11
    Sponsor Name:Hellenic GenitoUrinaty Cancer Group (HGUCG)
    Full Title: Intravesical administration of Durvalumab (MEDI4736) to patients with high-risk, non-muscle-invasive bladder cancer (NMIBC). A phase II study with correlative biomarker studies.
    Medical condition: Non-muscle-invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000221-31 Sponsor Protocol Number: DS8201-A-U301 Start Date*: 2019-02-06
    Sponsor Name:Daiichi Sankyo Inc.
    Full Title: A Phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (DS-8201a), an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER...
    Medical condition: Unresectable/metastatic breast cancer with human epidermal growth factor receptor 2 (HER2)-positive expression
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) CZ (Completed) FR (Completed) GR (Completed) DE (Completed) IT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-002573-35 Sponsor Protocol Number: OZM-058 Start Date*: 2019-08-30
    Sponsor Name:University Health Network, Toronto
    Full Title: A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients with Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer.
    Medical condition: Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-018161-12 Sponsor Protocol Number: SPD503-315 Start Date*: 2010-12-23
    Sponsor Name:Shire Development Inc
    Full Title: A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adol...
    Medical condition: Attention-Deficit/Hyperactive Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10068451 ADHD, combined type LLT
    14.1 100000004873 10068453 ADHD, predominantly inattentive type LLT
    14.1 100000004873 10068452 ADHD, predominantly hyperactive-impulsive type LLT
    14.1 100000004873 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) ES (Completed) SE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015565-31 Sponsor Protocol Number: 4305-009 Start Date*: 2009-12-03
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients with Primary Insomnia
    Medical condition: Primary Insomnia
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036701 Primary insomnia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed) BE (Completed) FI (Completed) DK (Completed) HU (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005697-71 Sponsor Protocol Number: 060402 Start Date*: 2006-01-26
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method (rAHF PFM): A Phase 3/4, Prospective, Controlled, Randomized, Multi-Center Study to Compare the Efficacy and Safety of Continuous Infu...
    Medical condition: Subjects with Severe or Moderately Severe Hemophilia A (baseline factor VIII (FVIII) level <= 2% of normal) hemophilia A undergoing major orthopedic surgery
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10060612 Hemophilia A LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) BE (Completed) PT (Completed) ES (Completed) HU (Completed) NL (Completed) GB (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002419-48 Sponsor Protocol Number: GETNE-T2216 Start Date*: 2023-03-27
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
    Full Title: Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
    Medical condition: Patients with radioiodine-refractory differentiated thyroid cancer (DTC).
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016935 Follicular thyroid cancer PT
    24.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001955-37 Sponsor Protocol Number: CQAB149B2335S Start Date*: 2007-04-29
    Sponsor Name:Novartis Farmacéutica S.A
    Full Title: Estudio multicéntrico, aleatorizado, doble ciego, doble enmascarado, controlado con placebo, con grupos paralelos y diseño adaptativo, de 26 semanas de tratamiento, para evaluar la eficacia, seguri...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002478-19 Sponsor Protocol Number: SHP616-300 Start Date*: 2016-06-28
    Sponsor Name:Shire ViroPharma, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Este...
    Medical condition: hereditary angioedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-003786-20 Sponsor Protocol Number: S320.2.011 Start Date*: Information not available in EudraCT
    Sponsor Name:Solvay Pharmaceuticals, Inc.
    Full Title: A Double-Blind, Placebo-Controlled, Randomized, Multi-Center, Dose-Finding Study of SLV320, a Selective A1 Adenosine Receptor Antagonist, to Evaluate the Effect on Renal Function and Safety in Subj...
    Medical condition: Acute Decompensated Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064653 Acute decompensated heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) DK (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-006538-16 Sponsor Protocol Number: A6181114 Start Date*: 2007-03-30
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017, US
    Full Title: AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNI...
    Medical condition: Malignant Gastrointestinal Stromal Tumor (GIST), Metastatic Breast Cancer, Metastatic Renal Cell Cancer, Pancreatic Neuroendocrine Tumor, Hepatocellular Carcinoma, Prostate Cancer, Thyroid Cancer, ...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027655 Miscellaneous and site unspecified neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FR (Completed) DK (Prematurely Ended) GB (Completed) NL (Prematurely Ended) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-003858-25 Sponsor Protocol Number: MK-5172-052 Start Date*: 2014-03-10
    Sponsor Name:Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection and Chronic Kidney D...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004848 10019183 HCV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) ES (Completed) SE (Completed) EE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-003640-11 Sponsor Protocol Number: MK0431C-102 Start Date*: 2008-10-30
    Sponsor Name:MERCK & CO., INC.
    Full Title: A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control.
    Medical condition: Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049746 Insulin-requiring type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SI (Completed) AT (Completed) LT (Completed) EE (Completed) LV (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-000203-41 Sponsor Protocol Number: AC-052-391 Start Date*: 2011-09-06
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: Multicenter, double-blind, placebo-controlled, randomized, prospective study of bosentan as adjunctive therapy to inhaled nitric oxide in the management of persistent pulmonary hypertension of the ...
    Medical condition: Persistent Pulmonary Hypertension of the Newborn (PPHN)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004850 10053592 Newborn persistent pulmonary hypertension LLT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Not Authorised) CZ (Prematurely Ended) GB (Completed) FR (Ongoing) BE (Prematurely Ended) PL (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-002529-23 Sponsor Protocol Number: 0431A-170 Start Date*: 2011-12-30
    Sponsor Name:Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co.
    Full Title: MK-0431A Protocol 170-04: “A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy MK-0431A (A Fixed-Dose Combination Tablet of Si...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Completed) LT (Prematurely Ended) GB (Completed) IT (Completed) DE (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003528-39 Sponsor Protocol Number: V503-001 Start Date*: 2007-11-15
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavi...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, ...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Completed) SE (Completed) DE (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001909-14 Sponsor Protocol Number: APL-B-021-13 Start Date*: 2016-03-14
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Phase II Study of Plitidepsin in Patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma.
    Medical condition: Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002453 Angioimmunoblastic T-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005616-40 Sponsor Protocol Number: 0941-017 Start Date*: 2009-02-03
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Phase IIa, Multicenter, Double-Blind, Randomized, Active-Controlled, Parallel-Arm Clinical Trial to Study the Efficacy and Safety of MK-0941 Compared to Sulfonylurea in Patients with Type 2 Diabe...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) IE (Completed) FI (Completed) EE (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 00:25:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA